Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
Citations
14 citations
13 citations
Cites background from "Reduction in Physician Reimbursemen..."
...Although the prostate-specific antigen (PSA) test has led to a stage migration with increased low- to intermediate-risk localized disease, about 10% of the patients are still found with metastatic disease at diagnosis [4]....
[...]
11 citations
Cites background or methods or result from "Reduction in Physician Reimbursemen..."
...Consistent with other studies, we found that GnRH agonist overuse declined precipitously over the 2000s, coincident with reimbursement policy changes (8, 13)....
[...]
...Whereas oncologists’ response to MMA cuts was to increase the use of recommended chemotherapies (11, 12), urologists maintained GnRH agonist use in patients for whom it was recommended but decreased overuse in patients for whom it was non-recommended (8)....
[...]
...Rates of overuse found in this study were between other published estimates and reflected a blending of two previously published sampling strategies and outcome definitions (8, 13)....
[...]
...Because of changes in staging over the study period, the cohort excluded men diagnosed with 1) T1 or T2 cancers with Gleason scores 8–10; 2) T2b tumors before 2002 when the staging definition changed; 3) T2c tumors after 2002 when the category was added; or, 4) T3a tumors(8)....
[...]
...Despite scant data supporting clinical effectiveness, GnRH agonist use in localized disease grew steadily from the 1990s, peaking in 2003 (8)....
[...]
10 citations
Cites background from "Reduction in Physician Reimbursemen..."
...Although evidence is limited on how such reimbursement policies would affect treatment decisions, two studies of physicians’ responses to reductions in Medicare payment rates for treatment of prostate cancer patients found that physicians maintained treatment for clinically appropriate cases and reduced it for less appropriate cases [35,36]....
[...]
10 citations
References
39,961 citations
"Reduction in Physician Reimbursemen..." refers methods in this paper
...Comorbidity was classified using a modification of the Charlson comorbidity index for use with Medicare data (19,20)....
[...]
3,500 citations
1,692 citations
"Reduction in Physician Reimbursemen..." refers background in this paper
...AST, delivered as a depot injection of luteinizing hormone– releasing hormone, is indicated for management of prostate cancer in two clinical situations, as palliative therapy in metastatic prostate cancer (6) or in combination with external beam radiotherapy in the treatment of locally advanced prostate cancer (7), for which it has been shown to improve survival....
[...]
1,602 citations
"Reduction in Physician Reimbursemen..." refers methods in this paper
...Comorbidity was classified using a modification of the Charlson comorbidity index for use with Medicare data (19,20)....
[...]
1,505 citations